A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

NCT01309789 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large-Cell, Anaplastic
Lymphoma, NK-cell
Lymphoma, T-cell

Interventions

DRUG: brentuximab vedotin
DRUG: cyclophosphamide
DRUG: brentuximab vedotin
DRUG: prednisone
DRUG: cyclophosphamide
DRUG: doxorubicin
DRUG: doxorubicin
DRUG: prednisone
DRUG: vincristine

Sponsor

Seagen Inc.

Collaborators

[object Object]